Reversal of the immunosuppressive tumor microenvironment via platinum-based neoadjuvant chemotherapy in cervical cancer

• Published in: Cancer pathogenesis and therapy Vol. 2; no. 1; pp. 38 - 49
• Main Authors: Feng, Xue, Meng, Xiaolin, Tang, Dihong, Guo, Shuaiqingying, Liao, Qiuyue, Chen, Jing, Xie, Qin, Liu, Fengyuan, Fang, Yong, Sun, Chaoyang, Han, Yingyan, Ai, Jihui, Li, Kezhen
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.01.2024; Department of Gynecological Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430000, China%National Clinical Research Center for Obstetrics and Gynecology, Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430000, China%Department of Gynecologic Oncology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan 410000, China; Elsevier
• Subjects: CD8; Cervical cancer; Neoadjuvant chemotherapy; Regulatory T cells; Spatial architecture; Tumor immune microenvironment; Neoadjuvant chemotherapy; Tumor immune microenvironment; Regulatory T cells; CD8; Cervical cancer; Spatial architecture; NACT; PR; Tregs; TIME; CR; SD; ACT; PD

Immunotherapy favors patients with tumors; however, only 3–26.3% of patients with cervical cancer benefit from single-agent immune checkpoint inhibitors. Combined immunotherapy and chemotherapy has been explored against tumor; however, the combination remains controversial. This study aimed to inves...